Abstract
There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Current Pharmaceutical Design
Title: Cognitive Behavioral Therapy in Prodromal Psychosis
Volume: 18 Issue: 4
Author(s): Jean Addington, Catherine Marshall and Paul French
Affiliation:
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Abstract: There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Export Options
About this article
Cite this article as:
Addington Jean, Marshall Catherine and French Paul, Cognitive Behavioral Therapy in Prodromal Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316082
DOI https://dx.doi.org/10.2174/138161212799316082 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews The Possible Role of Pathogenic and Non-Pathogenic Bacteria in Initiation and Exacerbation of Celiac Disease; A Comprehensive Review
Current Pharmaceutical Biotechnology Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology Oxidative Stress in the Hypothalamus: the Importance of Calcium Signaling and Mitochondrial ROS in Body Weight Regulation
Current Neuropharmacology Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry In Silico Prediction of Adverse Drug Reactions and Toxicities Based on Structural, Biological and Clinical Data
Current Drug Safety Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach
Current Pharmaceutical Design Interaction of NO and VIP in Gastrointestinal Smooth Muscle Relaxation
Current Pharmaceutical Design Prostacyclin Receptor Regulation --- from Transcription to Trafficking
Current Molecular Medicine Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Diagnosis and Treatment of Common Sleep Disorders in Adolescence
Adolescent Psychiatry Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Saturation of the Human Phenome
Current Genomics A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Camptothecins and Key Lessons in Drug Design
Drug Design Reviews - Online (Discontinued)